<DOC>
	<DOCNO>NCT01822041</DOCNO>
	<brief_summary>This study healthy human volunteer determine absorption , metabolism , excretion ( AME ) profile ARN-509 well absolute oral bioavailability ( BA ) .</brief_summary>
	<brief_title>14C-ARN-509 Microtracer Label AME Absolute BA Study</brief_title>
	<detailed_description>Two cohort 6 healthy volunteer enrol AME absolute BA part , respectively . The dose cohort 240 mg . The expected exposure dose 7-fold low steady state reach patient castration-resistant prostate cancer .</detailed_description>
	<criteria>Key 1 . Gender : male 2 . Age : 50 80 year , inclusive 3 . Body Mass Index ( BMI ) : 18.530.0 kg/m2 4 . Ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` power drink '' ) , grapefruit ( juice ) tobacco product 48 h prior entry clinical research center discharge 5 . Medical history without major pathology Key 1 . Evidence clinically relevant pathology . 2 . Mental handicap . 3 . History relevant drug and/or food allergy . 4 . Regular/routine treatment nontopical medication within 30 day prior entry clinical research center . 5 . Smoking . 6 . History alcohol abuse drug addiction ( include soft drug like cannabis product ) . 7 . Use concomitant medication , except acetaminophen ( paracetamol ) topical medication 8 . Irregular defecation pattern ( less per 2 day ) . 9 . Positive drug screen ( opiate , methadone , cocaine , amphetamine , cannabinoids , barbiturate , benzodiazepine , alcohol ) . 10 . Intake 24 unit alcohol per week ( one unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) . 11 . Positive screen HBsAg , antiHCV antiHIV 1/2 . 12 . Illness within five day prior drug administration .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>mass balance study</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>